Search results
Showing 2656 to 2670 of 8935 results
Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma
In development Reference number: GID-HTG10153 Expected publication date: TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
In development Reference number: GID-IPG10441 Expected publication date: TBC
In development Reference number: GID-TA11817 Expected publication date: 09 July 2026
We are listening to your views on this Highly specialised technology. Comments close 24 February 2026.
In development Reference number: GID-HTE10067 Expected publication date: 20 May 2026
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development Reference number: GID-HST10062 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
In development Reference number: GID-HTE10080 Expected publication date: 03 February 2027
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: 22 April 2026
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making